These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 33140729)

  • 21. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
    Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
    Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anthracyclines and the heart].
    Mazzarello GP; Morra L
    Recenti Prog Med; 1998 Sep; 89(9):459-64. PubMed ID: 9796378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins to prevent anthracycline-related myocardial toxicity: The jury is still out.
    Mandalà M; Bartolini C; Becattini C
    Eur J Intern Med; 2024 Aug; 126():41-42. PubMed ID: 38852023
    [No Abstract]   [Full Text] [Related]  

  • 26. Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.
    Piska K; Koczurkiewicz P; Bucki A; Wójcik-Pszczoła K; Kołaczkowski M; Pękala E
    Invest New Drugs; 2017 Jun; 35(3):375-385. PubMed ID: 28283780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
    Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
    Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human heart cytosolic reductases and anthracycline cardiotoxicity.
    Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
    IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.
    Schwach V; Slaats RH; Passier R
    Front Cardiovasc Med; 2020; 7():50. PubMed ID: 32322588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac toxicity after anthracycline chemotherapy in childhood.
    Iarussi D; Indolfi P; Galderisi M; Bossone E
    Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular disease in survivors of childhood cancer.
    Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
    Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of Chemotherapy Induced Cardiomyopathy.
    Payne DL; Nohria A
    Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiotoxicity in anthracycline therapy: Prevention strategies.
    Cruz M; Duarte-Rodrigues J; Campelo M
    Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiotoxicity of anthracycline therapy: current perspectives.
    Valcovici M; Andrica F; Serban C; Dragan S
    Arch Med Sci; 2016 Apr; 12(2):428-35. PubMed ID: 27186191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthracycline-dependent cardiotoxicity and extracellular matrix remodeling.
    Nikitovic D; Juranek I; Wilks MF; Tzardi M; Tsatsakis A; Tzanakakis GN
    Chest; 2014 Oct; 146(4):1123-1130. PubMed ID: 25288002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetogenic Action of Statins: Mechanisms.
    Carmena R; Betteridge DJ
    Curr Atheroscler Rep; 2019 Apr; 21(6):23. PubMed ID: 31037345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins and cancer.
    Vallianou NG; Kostantinou A; Kougias M; Kazazis C
    Anticancer Agents Med Chem; 2014 Jun; 14(5):706-12. PubMed ID: 24295174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
    Conklin KA
    Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.